GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Personalis Inc (STU:04X) » Definitions » EV-to-EBITDA

Personalis (STU:04X) EV-to-EBITDA : -0.14 (As of May. 11, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Personalis EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Personalis's enterprise value is €12.94 Mil. Personalis's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-89.86 Mil. Therefore, Personalis's EV-to-EBITDA for today is -0.14.

The historical rank and industry rank for Personalis's EV-to-EBITDA or its related term are showing as below:

STU:04X' s EV-to-EBITDA Range Over the Past 10 Years
Min: -56.17   Med: -3.46   Max: 3.81
Current: -0.14

During the past 7 years, the highest EV-to-EBITDA of Personalis was 3.81. The lowest was -56.17. And the median was -3.46.

STU:04X's EV-to-EBITDA is ranked worse than
100% of 116 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.51 vs STU:04X: -0.14

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Personalis's stock price is €1.495. Personalis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.089. Therefore, Personalis's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Personalis EV-to-EBITDA Historical Data

The historical data trend for Personalis's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Personalis EV-to-EBITDA Chart

Personalis Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -11.16 -34.95 -6.98 0.25 -0.41

Personalis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 -0.28 -0.03 0.14 -0.41

Competitive Comparison of Personalis's EV-to-EBITDA

For the Diagnostics & Research subindustry, Personalis's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Personalis's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Personalis's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Personalis's EV-to-EBITDA falls into.



Personalis EV-to-EBITDA Calculation

Personalis's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=12.939/-89.863
=-0.14

Personalis's current Enterprise Value is €12.94 Mil.
Personalis's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-89.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Personalis  (STU:04X) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Personalis's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.495/-2.089
=At Loss

Personalis's share price for today is €1.495.
Personalis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.089.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Personalis EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Personalis's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Personalis (STU:04X) Business Description

Traded in Other Exchanges
Address
6600 Dumbarton Circle, Fremont, CA, USA, 94555
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Liquid Biopsy, NeXT Dx Test, and other Pharma Research Solutions.

Personalis (STU:04X) Headlines

No Headlines